Corvus Pharmaceuticals, Inc.
CRVS
CRVS: Corvus Pharmaceuticals Inc is a clinical-stage biopharmaceutical engaged in developing drugs and antibodies that target the most critical cellular elements of the immune system. It focuses on the development of immune modulator product candidates to treat COVID-19, T-cell lymphomas, other cancers and autoimmune diseases. The company's lead product candidate is CPI-006 which is a potent humanized monoclonal antibody that is designed to react with a specific site on CD73. Its other product candidates are CPI-818, CPI-935, CPI-182 and Ciforadenant.
moreShow CRVS Financials
Recent trades of CRVS by members of U.S. Congress
Recently reported changes by institutional investors
Quarterly net insider trading by CRVS's directors and management
Government lobbying spending instances
New patents grants
-
Patent Title: Pharmaceutical formulations Mar. 08, 2022
-
Patent Title: Compounds and methods for modulating adenosine a2b receptor and adenosine a2a receptor Feb. 22, 2022
-
Patent Title: Methods of treating cancer Jun. 22, 2021
-
Patent Title: Compounds and methods for modulating interleukin-2-inducible t-cell kinase May. 18, 2021
-
Patent Title: Methods of treating cancer Feb. 09, 2021
-
Patent Title: Compounds and methods for modulating bruton's tyrosine kinase Dec. 22, 2020
-
Patent Title: Humanized anti-cd73 antibodies Nov. 03, 2020
-
Patent Title: Anti-cd73 antibodies Oct. 06, 2020
-
Patent Title: Processes for making triazolo[4,5d] pyramidine derivatives and intermediates thereof May. 19, 2020
Federal grants, loans, and purchases
Followers on CRVS's company Twitter account
Number of mentions of CRVS in WallStreetBets Daily Discussion
Recent insights relating to CRVS
Recent picks made for CRVS stock on CNBC
ETFs with the largest estimated holdings in CRVS
Flights by private jets registered to CRVS